{"name":"Bone Therapeutics S.A","slug":"bone-therapeutics-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ALLOB® cells with ceramic scaffold","genericName":"ALLOB® cells with ceramic scaffold","slug":"allob-cells-with-ceramic-scaffold","indication":"Treatment of non-unions and delayed unions of long bones","status":"phase_2"},{"name":"ALLOB® implantation","genericName":"ALLOB® implantation","slug":"allob-implantation","indication":"Other","status":"phase_1"},{"name":"JTA-004","genericName":"JTA-004","slug":"jta-004","indication":"Acute bone fractures (femoral shaft fractures)","status":"phase_3"}]}],"pipeline":[{"name":"ALLOB® cells with ceramic scaffold","genericName":"ALLOB® cells with ceramic scaffold","slug":"allob-cells-with-ceramic-scaffold","phase":"phase_2","mechanism":"ALLOB cells with ceramic scaffold are a type of cell therapy that uses autologous mesenchymal stem cells to promote bone healing and regeneration.","indications":["Treatment of non-unions and delayed unions of long bones"],"catalyst":""},{"name":"ALLOB® implantation","genericName":"ALLOB® implantation","slug":"allob-implantation","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JTA-004","genericName":"JTA-004","slug":"jta-004","phase":"phase_3","mechanism":"JTA-004 is an allogeneic cell therapy derived from bone marrow-derived mesenchymal stem cells that promotes bone regeneration and repair.","indications":["Acute bone fractures (femoral shaft fractures)","Bone defects and non-union fractures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOLVlJc3JXdTZCR3pKMHhLclJMV0NhYksyQzJjZm5vOENGSUFQRzFIdHBvdzFvYXB3a3pSWGQ3RWtHZEpHMEJJcHZJXy1HdnNsejQ3TzV0bmZoenBMeFBCbjZwWERaekl3ZVJ4amcxNDlkZzJlM2V4VXgwLVdKSnhXYzFMSUVtcUkzNHlTei1IM254eF9TeHBQZzJR?oc=5","date":"2026-04-06","type":"trial","source":"openPR.com","summary":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust - openPR.com","headline":"Knee Osteoarthritis Clinical Trial Pipeline Appears Robust","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxPNVRSMUtERVNLT3BpVk9iVkJnS1ZNdFc5QmZIOXVtcTdFcFVtaWtqRnB5WVNpRGp1WE8yNkYwYUMyZFlnaXAyaG5abXlPZS0tZXdIWlZvTmZ0ci1od0VHZkM1cE41bXRmaWFjVzFwcTVZbFdISWMwZ0gxc0hYZW9KZnJBLV9aYXQzdXV3S2E2c0pmOElDRnNzRlJiOHlxMURoYUdjR0tnNUFzNUdZSTNOUGpDRFJwU0lFY2RHTnpuQWlfUDhiVm04RXVDVlFFUV9IczM2cEtlWDJWbVZTQlR2dDkzOURkZ29IWUZuUFJHbll2TXhuYU42ZFRpSVloVG9QVE0tSl93Z21sdVNRLXNTcURZdUNmUGc2czRIcTZETTUxbllPTTNjV1FuNG5MWWQzVTA3V3Q2SVFLZTE5TGRFeFpwQ0l1eTlQbUxsbl9uYw?oc=5","date":"2026-03-25","type":"trial","source":"Barchart.com","summary":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stages, Finds DelveInsight | Biosplice Therapeutics, Regeneron Pharmaceuticals - Barc","headline":"Osteoarthritis Clinical Trial Pipeline Advances as 100+ Companies Develop 110+ Novel Therapies Across All Clinical Stage","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"globenewswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - globenewswire.com","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPN0dzMUxzYXZ4ZWhOTTJoYkdRS0xaU0hKVldQYkdWaktBcERwaTk4RDEycEZCOHZ3T1VIXzg4MzgxZ3VLUG1jdE1Hc1g1S0s5UEJ5OTBfWmJWRE5MOU1oR0RnYW91cWRCb0ZDaTgtX1RUSllnUThDUlFyUklFTlpncA?oc=5","date":"2025-12-09","type":"pipeline","source":"MarketsandMarkets","summary":"Radioligand Therapy (RLT) Market worth $10.91 billion by 2035 - MarketsandMarkets","headline":"Radioligand Therapy (RLT) Market worth $10.91 billion by 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOYXM2QTdfbmJwVURFUnBPWXp0REUyblpQNXVXQ1NrY2IwVjdlQzFGaGhmcmZiclZoU0RBQzU0YV9UNmltUVRMX0ZHMEFhU3FzemVjQ1FrcmZ6YllSdmpqM3ROa19fQU1HTzc3SHBBQmFNYXgwaEdPZUNSX3I3RHd0N040MHRiSG95THF6M2FtMDhwQUxSNHhWQWpJNDZvdW9tLU5fT2k3UmQ2MC1kYXZ4ZkVPcC1lMlhHWlhWaEtKOG9HYjFTeFJvdzk2djd1RjVTQUR3LU1sclEwSzJiYUFBN3F3aG1tbXkzckFiT2xzV2VfQjJEY2tNRy02dEp3elFYQmg5Njk0ZThfMEs4eEhYaDhXMFRqVWd2VXdjMXZER0JQVXVVY0VrNGpn?oc=5","date":"2025-07-30","type":"pipeline","source":"PR Newswire","summary":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight - PR Newswire","headline":"Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technologi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQRS05UlEwNC03d3VZaGJrTHZ4U2h2T0VFNzJidElEZ2ZxVFRlb1hpQ3dmQUhDeW1PcHVmTWtDX3BoLUZaN0E2LWhvb1N3ay1uVFdQMkd1b1pPNHJiRHpNaHRtTmk5cURjSnp5VVp1VExpcVhFMVktNFVXX3JrUHU1dm4tMWhSTk92V0paTGdoVGlhTUQwcjFuNEx1VlRXYmhRejlFRHQ4MS1UMkNxSlQweDlUTTlpU2V3aFBnV1llN2V4U3ZfdTZvWkNwb3ZLZzVTekhkZ3lDSmhGNjFSQjdTSE5HVnRZdWFJV29MV0ZneFN0cmUySHZBQWN4UWotZw?oc=5","date":"2025-06-18","type":"regulatory","source":"PR Newswire","summary":"Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Osteoarthritis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQSzVTM1VUelpGQzFYVHA5MUNreGxfRUlXZjl3UFRZaXRXckNJT2dyU0w5bExWeGxkVHZSZmVjcF8yVV9mZlRaSzhqaGdLRVAxczJIQlVUdG1ZMnNTa3pQdGdtb0k5VVBWQklqeUd3R3VQZGlSdnN4QS1VejZxZTZHY2gxOXR2Nkc2WHN1OHR3?oc=5","date":"2024-03-07","type":"pipeline","source":"Frontiers","summary":"Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient - Frontiers","headline":"Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE5WTml6RWlkdFNlcElfTFRnUFpsZURTWU9tWmo5UlBEemg3M29yYUlDeHY4bEVJbjQ0QVJtaHJFUnAxRkdReTdzRndwTnktNF84cGw5VmVLTTBZNmEzS0I1TFp0bkpiSXBRdEZrVA?oc=5","date":"2022-11-21","type":"pipeline","source":"Fierce Biotech","summary":"The 2022 Biotech Graveyard - Fierce Biotech","headline":"The 2022 Biotech Graveyard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPaENKVWFGMHJpd1FWZlNTeFB6YzktMnZfeENfU3BfZXE4ZkpQSksxd0hEWVFrSWJUNG5VZGxBMUpmeDh2cUJLZnlGSkpQSnYxbkxfQXZlbTg0MjBIZXlvLUl4aFdUMlYwOXUtalVjd1hwbUhjMGtxUWhOZTBjZ3hSb0ZzZ29rVzQzZ1BpdHZFZFpWYV8xTGV3dzhmWFk0czJuYXYxT3RlR21XVWJQVl9fMkE3dTh5UQ?oc=5","date":"2022-11-02","type":"patent","source":"BioWorld News","summary":"Rhizen Pharmaceuticals and Incozen Therapeutics patent new PARP inhibitors - BioWorld News","headline":"Rhizen Pharmaceuticals and Incozen Therapeutics patent new PARP inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOa01RSlB0Z2htYWc4ZXN0ZU01QzVFaUZSYkVrWmVMZ21lMVA3QzBxc3FfU0U4Z2o5eHJQR3l5aXN4OEU4ZFp4dkYwSE0wODVHZHNxU25ZUUx5NERMUDhBemF5VmZoSXVCYnhlRm8wVmV1aU9QTmhyWmpfOWY0dkNxOEdrdmx4cjZFSEYzOGxFcDZRaVJVR2U3V1cxMms5aGozRU1JbEVFdUdRY1FxTkYzd2FiaEVxYk5DOU11bnRBdDRjeUF6?oc=5","date":"2022-10-26","type":"pipeline","source":"Fierce Pharma","summary":"Bone Therapeutics joins biotech name change rage, rebranding as BioSenic - Fierce Pharma","headline":"Bone Therapeutics joins biotech name change rage, rebranding as BioSenic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNV0stc0NydjhmU3JHSDFaeDFULVA4WFg0aURRUjc5a053bGVfaTBST3U4X2F0WGZlVmhyQjdwSHNXUGU4SWhyVWhaQVZaVk1PZXFfbkRJQ0kwR2JXMWFjVjJiTG9oYmZscWJJMTNHRHFkczJuX3RtdWhtX2x1U1dVSkxNSWxHYVdSSVVRbTdNbnktaGJtNkM3Q2xud0txYmNVV194VXhB?oc=5","date":"2022-10-25","type":"pipeline","source":"European Biotechnology Magazine","summary":"Bone Therapeutics merges with Medsenic and changes name - European Biotechnology Magazine","headline":"Bone Therapeutics merges with Medsenic and changes name","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNd2ZlQnBYcmFSSjJVYWJqOVAwY3dvTWRvV0hOVWpjc3h6TWIxMHdPRjFYcmR5UWQ0cDdZM2lDWmo2R3BEQVJFaFo4NzFvX0J0RmI5bFBaYUVibWFLdmtHZ0JaNTVGWHZrS0JfenRHdEhPUkpDVTQ0X2dHblRSakxlZlVLU0owZGhnSlVCeEdXT2NKMlJyQzZKR1JKekZ2Z0d5QkF1SjVTSVZBa2M4b2c?oc=5","date":"2020-10-29","type":"deal","source":"Contract Pharma","summary":"Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility - Contract Pharma","headline":"Catalent to Acquire Bone Therapeutics’ Cell Therapy Mfg. Facility","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}